Last edited by Tygonris
Wednesday, July 8, 2020 | History

3 edition of Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity. found in the catalog.

Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity.

National Cancer Institute (U.S.). Division of Cancer Cause and Prevention.

Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity.

by National Cancer Institute (U.S.). Division of Cancer Cause and Prevention.

  • 322 Want to read
  • 35 Currently reading

Published by Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, Division of Cancer Cause and Prevention, Carcinogenesis Testing Program in Bethesda, Md .
Written in English

    Subjects:
  • Carcinogens.,
  • Hypotensive agents -- Toxicology.

  • Edition Notes

    SeriesCarcinogenesis technical report series ; no. 72, DHEW publication ; no. (NIH) 78-1322, DHEW publication -- no. (NIH) 78-1322.
    The Physical Object
    Paginationxi, 90 p. :
    Number of Pages90
    ID Numbers
    Open LibraryOL15223263M

    Phenoxybenzamine HCl. For research use only. Catalog No.S Synonyms: NSC , NCI-c provides accurate and independent information on more t prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 30 June ), Cerner Multum™ (updated 1 July ), Wolters Kluwer.

    NTP. Phenoxybenzamine hydrochloride (). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National Toxicology Program (NTP). Accessed The Hazard fields include special hazard alerts air and water reactions, fire hazards, health hazards, a reactivity profile, and details about reactive groups assignments and potentially incompatible information in CAMEO Chemicals comes from a variety of data sources.

    National Cancer Institute (NCI) () Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity. Public Health Service, National Institutes of Health, Department of Health, Education, and Welfare, Washington (Technical report no 72) Google Scholar. Phenoxybenzamine is used to control blood pressure and reduce sweating in people with pheochromocytoma (tumor of the adrenal gland). Phenoxybenzamine may also be used for purposes not listed in this medication guide.


Share this book
You might also like
host-parasite catalog of North American Tachinidae (Diptera)

host-parasite catalog of North American Tachinidae (Diptera)

Studies of apartment parking need

Studies of apartment parking need

Hannah Ann

Hannah Ann

Women and microcredit in rural Bangladesh

Women and microcredit in rural Bangladesh

As Good as Anybody

As Good as Anybody

César Franck

César Franck

Co_ Aytch, A Side Show of the Big Show

Co_ Aytch, A Side Show of the Big Show

Christians in Conflict - The Dialog Series

Christians in Conflict - The Dialog Series

Approaches to improving the quality of life

Approaches to improving the quality of life

Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity by National Cancer Institute (U.S.). Division of Cancer Cause and Prevention. Download PDF EPUB FB2

BIOASSAY OF PHENOXYBENZAMINE HYDROCHLORIDE FOR POSSIBLE CARCINOGENICITY. Carcinogenesis Testing Program. Division of Cancer Cause and Prevention National Cancer Institute National Institute osf Health. FOREWORD; Thi reporst present th resultse osf th bioassae oyf phenoxybenzamine hydrochloride conducte for th Carcinogeneside s.

Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity (CASRN ) Chemical (Study Title) CASRN Peer Review Date Route/Exposure Levels Study Laboratory; Phenoxybenzamine hydrochloride 03/07/ Intraperitoneal Injection R: 0,5,10, M: 0,25 MG/KG/35 PER GROUP. Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity.

Technical Report Series no. DHEW Publication No. (NIH) Bethesda, MD: National Cancer Institute. Nettesheim O, Hoffken G, Gahr M, Breidert M. [Haematemesis and dysphagia. Long-Term Carcinogenicity. 2-Year (Intraperitoneal Injection) (C) Completed.

TR (NIH Number: ) (Peer Review Approval 03/07/A) Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity (CASRN ) Rats: Sprague Dawley; Mice: B6C3F1; Carcinogenesis Results. Male Rats Positive. Phenoxybenzamine hydrochloride IARC carcinogenicity IARC Group 2B Possibly carcinogenic to humans.

Reproductive toxicity Reproductive toxicity - fertility Based on available data the classification criteria are not met. Reproductive toxicity - development.

The labeling for the proprietary oral dosage form of phenoxybenzamine, Dibenzyline, carries a warning regarding possible carcinogenic and mutagenic risks, as observed in in vitroand small animal testing (WellSpring Pharmaceutical Corporation, Sarasota, FL).

Under the conditions of this bioassay, phenoxybenzamine hydrochloride was carcinogenic (sarcomagenic) for the peritoneum of both sexes of Sprague-Dawley rats and B6C3F1 mice.

Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity () Technical Rpt Series No. 72 DHEW Pub No. (NIH)U.S. Department of Health Education. The hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties.

Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Carcinogenicity Repeated intraperitoneal administration of phenoxybenzamine to rats and mice caused peritoneal sarcomas, and chronic oral dosing in rats caused malignant tumors of the gastrointestinal tract (primarily in the nonglandular stomach {01}).

α-Adrenergic blocking agent; a haloalkylamine. a b Uses for Phenoxybenzamine Hydrochloride Pheochromocytoma. Prevention or treatment of paroxysmal hypertension and sweating in patients with pheochromocytoma.

a b Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of hypertension caused by. Author(s): Southern Research Institute (Birmingham, Ala.); National Institutes of Health (U.S.); Carcinogenesis Testing Program (U.S.) Title(s): Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity.

Get this from a library. Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity. [National Cancer Institute (U.S.). Division of Cancer Cause and Prevention.]. Abstract A bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity was conducted by administering the test chemical by intraperitoneal injection to Sprague-Dawley rats and B6C3F1 mice.

Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity (OCoLC) Material Type: Document, Government publication, National government publication, Internet resource: Document Type: Internet Resource, Computer File: All Authors / Contributors: National Cancer Institute (U.S.).

Division of Cancer Cause and Prevention. National Cancer Institute () Bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity. NCI Carcinog Tech Rep Ser National Cancer Institute () Bioassay of reserpine for possible carcinogenicity.

Dept of Health, Education, and Welfare pub no (NIH) 80– () Bioassay program for carcinogenic hazards of. Phenoxybenzamine also has irreversible antagonist/weak partial agonist properties at the serotonin 5-HT 2A receptor.

Due to its 5-HT 2A receptor antagonism, phenoxybenzamine is useful in the treatment of carcinoid tumor, a neoplasm that secretes large amounts of serotonin and causes diarrhea, bronchoconstriction, and flushing.

Phenoxybenzamine Hydrochloride is the hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral.

Phenoxybenzamine hydrochloride: CAS Number: Relevant identified uses of the substance or mixture and uses advised against; Identified uses: For research use only, not for human or veterinary use. Details of the supplier of the safety data sheet; Company: Abmole Bioscience Inc.

FM West, Suite Houston, TXUSA. NTP. TR Phenoxybenzamine hydrochloride (). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National Toxicology Program (NTP). Accessed. Rep Carcinog.

;III Phenoxybenzamine hydrochloride. [No authors listed] Update of Rep Carcinog. ; PMID:. A bioassay of phenoxybenzamine hydrochloride for possible carcinogenicity was conducted by administering the test chemical by intraperitoneal injection to Sprague-Dawley rats and B6C3F1 mice.

Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity (CAS No. ) National Toxicology Program (NTP) Technical Report Series No. NIH Publication .Phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha-receptor blocking agent. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures.

It has no effect on the parasympathetic system. Indication: • Pheochromocytoma Hypertension (off-label) Contraindications.